The U.S. Centers for Medicare & Medicaid Services (CMS) has issued a National Coverage Determination (NCD) for transcatheter edge-to-edge repair (T‑TEER) of tricuspid regurgitation, meaning Abbott’s FDA-approved TriClip system is now covered under Medicare for eligible patients.
This move ensures more predictable reimbursement and opens the door to treatment for patients previously ineligible for open-heart surgery.
Find growth niches in minutes, not months.
Explore quick, actionable insights from the select markets.
Table of Contents
➜ What is Abbott’s TriClip Tricuspid Valve Repair System?
➜ CMS Coverage Decision for Abbott TriClip: Timeline and Details
➜ How Abbott TriClip Works for Tricuspid Valve Repair
➜ Medicare Coverage for Tricuspid Valve Repair: What Patients Need to Know
➜ Abbott vs Edwards Lifesciences: Tricuspid Valve Treatment Market
➜ Clinical Benefits of Abbott TriClip for Tricuspid Regurgitation
➜ Future of Tricuspid Valve Repair with CMS Coverage
➜ Get a Complimentary Cardiac Report Summary
Key Takeaways
- Historic Approval: CMS approved national Medicare coverage for Abbott’s TriClip system on July 8, 2025, marking the first Medicare coverage for transcatheter tricuspid valve repair
- Market Leadership: Abbott’s TriClip is currently the only FDA-approved device for T-TEER, giving the company a significant competitive advantage
- Patient Impact: Over 1.6 million Americans suffer from tricuspid regurgitation, and this coverage will make treatment accessible to Medicare beneficiaries
- Minimally Invasive: The procedure is performed through a vein in the leg, avoiding open-heart surgery
- Coverage with Evidence Development: CMS is requiring real-world data collection through the TRICARE study to monitor long-term outcomes
- Timeline: The approval process began in October 2024 and concluded ahead of the original July 2025 deadline
What is Abbott’s TriClip Tricuspid Valve Repair System?
Abbott’s TriClip system represents a breakthrough in minimally invasive cardiac treatment. Tricuspid regurgitation is a condition where the valve between the two right heart chambers doesn’t close properly, allowing blood to leak backward. It can reduce the amount of blood pumped through the body, causing the heart to work harder.
The TriClip system offers a minimally invasive treatment option to improve quality of life (QoL) and functional status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, who are at intermediate or greater risk for surgery.
📌 Learn More About Minimally Invasive Heart Surgery:
➜ Minimally Invasive Heart Surgery: Can TAVI & TMVr Replace Open Surgery for Good?
Key Features of Abbott TriClip:
- Delivered through a vein in the leg rather than requiring open-heart surgery
- Clips together valve leaflets to reduce regurgitation
- TriClip received FDA approval in April 2024
- Based on Abbott’s successful MitraClip platform for mitral valve repair
CMS Coverage Decision for Abbott TriClip: Timeline and Details
The path to Medicare coverage for Abbott’s TriClip system followed a comprehensive review process that demonstrated CMS’s commitment to evidence-based coverage decisions.
Coverage Timeline:
- April 2024: TriClip receives FDA approval
- October 2024: CMS begins national coverage analysis following Abbott’s formal request
- November 2024: Public comment period closes
- April 2025: CMS releases proposed decision memo
- July 8, 2025: Final coverage decision approved
The approval comes with specific requirements. CMS approved coverage under its Coverage with Evidence Development (CED) program, requiring participation in the TRICARE study (TRIClip CoverAge with Evidence Development Real-World Evidence Study) to collect long-term outcomes data.
How Abbott TriClip Works for Tricuspid Valve Repair
The TriClip system employs transcatheter edge-to-edge repair (T-TEER) technology, which represents a significant advancement in cardiac intervention techniques. Delivered through a vein in the leg, the TriClip TEER technology clips together a portion of leaflets. It repairs the tricuspid valve and helps blood flow in the right direction without the need for open-heart surgery.
Procedure Benefits:
- Ideal for patients at intermediate or high surgical risk
- Minimally invasive approach typically results in faster recovery times
- Many procedures can be performed as outpatient or short-stay procedures
- Repairs existing valve rather than replacing it
📌 Learn More About Types of Cardiac Surgeries in 2025:
Medicare Coverage for Tricuspid Valve Repair: What Patients Need to Know
The CMS coverage decision will have profound implications for Medicare beneficiaries suffering from tricuspid regurgitation. Medicare now covers TriClip procedures for patients with symptomatic tricuspid regurgitation, but there are specific criteria that must be met.
Tricuspid Valve Repair Coverage Requirements:
- Patients must have symptomatic severe tricuspid regurgitation
- Optimal medical therapy must have been attempted
- Patients should be at intermediate or greater surgical risk
- Treatment must be performed at qualified centers
- Participation in the TRICARE registry is required
Tricuspid Valve Repair Patient Impact:
With over 1.6 million Americans affected by tricuspid regurgitation, this coverage decision represents a significant expansion of treatment options. Previously, many patients faced limited alternatives, particularly those deemed too high-risk for traditional surgery.
📌 Related Read:
➜ Abbott’s Tendyne TMVR System Receives FDA Approval: The Future of Heart Valve Replacement
Abbott vs Edwards Lifesciences: Tricuspid Valve Treatment Market
The tricuspid valve treatment market has become increasingly competitive, with Abbott now holding a significant advantage through its CMS coverage.
Abbott’s Triclip U.S. launch followed shortly after Edwards Lifesciences gained FDA approval for its valve replacement device, called Evoque, to treat tricuspid regurgitation.
Fun Fact:
The structural heart market is experiencing unprecedented growth, with tricuspid interventions representing one of the fastest-growing segments. Abbott’s early CMS coverage provides a significant competitive moat that could take years for competitors to overcome.
Clinical Benefits of Abbott TriClip for Tricuspid Regurgitation
Clinical evidence supporting the TriClip system demonstrates significant improvements in patient outcomes. The device addresses a critical unmet need in cardiac care, particularly for patients who are not candidates for traditional surgical intervention.
Clinical Outcomes:
- Symptom Relief: Significant reduction in heart failure symptoms
- Quality of Life: Improved functional capacity and exercise tolerance
- Safety Profile: Low complication rates compared to surgical alternatives
- Durability: Long-term effectiveness demonstrated in clinical trials
Patient Selection Criteria:
The success of TriClip therapy depends on appropriate patient selection. Ideal candidates typically include patients with:
- Symptomatic severe tricuspid regurgitation
- Heart failure symptoms despite optimal medical therapy
- Intermediate to high surgical risk
- Appropriate valve anatomy for clip placement
Future of Tricuspid Valve Repair with CMS Coverage
The CMS coverage decision for Abbott’s TriClip system marks the beginning of a new era in tricuspid valve treatment. This approval is expected to catalyze broader adoption of minimally invasive cardiac interventions and drive innovation in the structural heart space.
Market Implications:
- Increased Access: Medicare coverage will significantly expand patient access to innovative treatment
- Provider Adoption: Hospitals and cardiac centers likely to expand structural heart programs
- Clinical Evidence: The required TRICARE registry will generate valuable real-world data
- Future Indications: Success may pave the way for expanded coverage criteria
Innovation Pipeline:
The approval also validates the broader transcatheter approach to structural heart disease, potentially accelerating development of next-generation devices and techniques.
Turn market painpoints into opportunities
Explore how procedure trends and competitor positioning create clear openings for industry experts in the market.
